Diagnamed Holdings Corp. announced a test launch of CERVAITM, a world-first consumer brain health and wellness AI solution, at the University of Miami Comprehensive Center for Brain Health. The initial focus will be evaluating the brain health assessment portion of CERVAITM, which scores brain health by taking a clinically validated assessment for brain resilience, vulnerability and performance functions.

CERVAITM's brain health assessment, developed by researchers led by Dr. James E Galvin, M.D., M.P.H at the University of Miami Miller School of Medicine, is designed to assess a patient's risk for developing Alzheimer's disease and other neurological issues, through an advanced series of tests that determine the risk for dementia by combining three measures --a Resilience Index, a Vulnerability Index ("VI") and a Number-Symbol Coding Task. The results, when combined, help assess the risk for developing AD and other related conditions. Essentially, it is intended to "take a snapshot" of a patient's brain health.

In a cross-sectional study, Galvin and colleagues evaluated 230 participants (71 controls, 71 with mild cognitive impairment, 88 with AD and related disorders). Researchers determined VI and RI scores from physical assessments, lifestyle questionnaires, demographics, medical history and neuropsychological examination, including the NSCT. Results showed that participants with abnormal test scores were 95.7% likely to be impaired, with a misclassification rate of 9.7%.

The platform outperformed the Montreal Cognitive Assessment with a high level of accuracy (area under the curve = 0.923 ± 0.053). The CERVAITM Brain Health test pilot program continues to be open to a select 25 clinics in the U.S. and Canada. Ideal clinics for the pilot program must focus on health and wellness, sports and physical therapy, mental health, chiropractic care, or clinical research for neurological and cognitive disorders.